




## Clinical Champions Programme

### August 2022 – Impact Report

#### Impact on Care

##### Project Areas

The graph below represents where along the prostate cancer pathway our Clinical Champions are driving improvements. Many of the champions are working across more than one area.



##### Project Highlights

Our Clinical Champions have reported on the progress of their projects and below are some examples of how they have benefitted men with prostate cancer:

###### Amarnath Challapalli's

Patients now have access to PSMA PET scanning.

Helped produce regional and national guidelines for indications for PSMA PET scans.

Engaging with radiotherapy Operational Delivery Network (ODN) in south-west to do a benchmarking exercise for regional centres with regards to access to PSMA diagnostics and to radioligand therapy.

###### Will Kinnaird

Increased patient participation in research way beyond all initial expectations.

Now have robust and large-scale data allowing us to clearly highlight the need for improvements in care for men with advanced prostate cancer.

This is the first research of its kind and should result in direct improvements to care.



### **Dr Stephen Mangar**

Established PSMA PET as routine staging for a subset of high-risk prostate patients.  
Published trial data on actigraphy- now second phase of study underway.

### **Vishwanath Hanchanale**

I have been able to establish my intended plan of LATP biopsy programme for the merged unit. Currently finalising the last few points to improve the RDS pathway.

### **Sam Worster**

Have been able to show the safe use of Spacers (Barrigel) at the same time as HDR brachytherapy, in a global first. Presented at ESTRO in Copenhagen this year.  
Submitted a complete business case to apply for funding for the service.  
Presented at European conferences and have been asked to publish data.

### **Nikhil Vasdev**

Robotic Prostatectomy and Nerve sparing in T3 prostate cancer.  
Has received 50K funding for an Artificial Intelligence MRI Trial (PAIR 2) and 40K funding for a urinary microfluidics biomarker in Prostate cancer during the programme.  
Has been able to get 3 additional pathologists trained to do frozen sections of prostate, set up a nerve sparing programme and have data on 70 patients,  
Performed his technique for nerve sparing robotic prostatectomy in New Delhi in Feb 2022

### **Darren Leaning**

Founded the UK Molecular Radiotherapy Consortium  
Involved with the "Utopia" trial for diagnostic imaging for LuPSMA treatment  
Developed "problem peeing you need seeing" campaign for Northern Cancer Alliance

## **Impact on Patient Experience**

"A snapshot audit suggests that the right patients are getting the PSMA scans and enabling identifying suitable patients for SABR" - Dr. Amarnath Challapalli.

"This research project has allowed us to give a voice to men who have previously been excluded from support. Men have expressed their gratitude at being given the opportunity to share their experiences and feelings. Their emotive and in-depth comments will help us to properly characterise men's experiences of sexual problems in advanced prostate cancer" - Will Kinnaird.

"PSMA imaging for high-risk prostate cancer has allowed for identification of oligometastatic disease that may go on to have stereotactic radiotherapy, or upstaged disease to allow them better systemic treatments for prostate cancer" - Dr Stephen Mangar.

"At the 2 year point we do not have any patients with gastrointestinal issues. Need to collect 5-year data however" – Sam Worster.



**Early indication suggests that over 11,110 patients will benefit from the improvements being driven by our clinical champions, naturally this number will continue to grow as projects go through their final stages of testing and implementation. Management & Leadership Development**

All participants indicated that they have benefitted from the Programme in terms of their personal development. This is evident from comments such as:

- “The taught modules have helped me focus on the importance of emphasis of word cues and body language”.
- “I have learnt that many of the struggles and battles we face in bringing about change are similar. Sharing and talking through challenges with peers helps to highlight common problems. This helps me recognise that problems should not be viewed as personal failures”.
- “The programme has been helpful for me personally in that it gives me a chance to share ideas and foster relationships with my peers, from outside my region. The regular sessions also help me to maintain focus on my projects and give me new approaches in dealing with obstacles that I encounter”.
- “Immensely helped me in developing leadership and interpersonal skills”.
- “I found the content from module 2 very impactful as it allowed me to reflect on and discover my own leadership style. I have found the support provided from PCUK and peer networking and support invaluable”.
- “Seeing how my personality type interacts with others”.
- “How to be a more effective leader. A better awareness of myself and improved confidence”.
- “Improvement in relationship with the team as a leader, listening to others, respecting everyone, highlight that all opinions count, developing skills for PESTLE analysis and being promoted to Trust Cancer lead”.
- “I am now helping to set up a UK molecular radiotherapy consortium and co-investigator on a national project for Lutetium PSMA”.

## **Programme Summary**

At this stage, the impact on the cohort, as defined by the participants themselves, is positive with the potential to further improve in terms of leadership and management development. The same can be said, with further evidence-based information available at the end of the Programme, on the impact of the individual projects.

At this stage we are also pleased to announce the recruitment of 20 new Clinical Champions who will make up our 2<sup>nd</sup> cohort of the programme. All champions have started the programme and are now in the process of finalising their project concepts and focus. We expect to start reporting on the progress for this group around November 2022.